TG Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advanc...
Latest News
2 days ago · fool.com
TG Therapeutics: 3 Key Takeaways for Long-Term InvestorsTG Therapeutics raised full-year 2026 global revenue guidance to $1 billion. Subcutaneous BRIUMVI could more than double peak sales opportunity.
6 days ago · zacks.com
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock UpTG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.
7 days ago · seekingalpha.com
TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call TranscriptTG Therapeutics, Inc. ( TGTX ) Q3 2026 Earnings Call November 9, 2026 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary & Treasurer Conference Call Participants Michael DiFiore - Evercore ISI Institutional Equities, Research Division Tara Bancroft - TD Cowen, Research Division Jiale Song - Jefferies LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Operator Greetings, and welcome to the TG Therapeutics Third Quarter 2026 Conference Call.
8 days ago · marketbeat.com
What TG Therapeutics (TGTX) Said on Its Q3 Earnings CallTG Therapeutics NASDAQ: TGTX raised its 2026 revenue outlook after third-quarter sales of its multiple sclerosis treatment BRIUMVI climbed 52% in the United States, and executives said they expect a stronger fourth quarter.
8 days ago · zacks.com
TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
8 days ago · zacks.com
TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue EstimatesTG Therapeutics (TGTX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $2.43 per share a year ago.
8 days ago · businesswire.com
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceNEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four ye.
15 days ago · businesswire.com
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business UpdateNEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the third quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnin.
22 days ago · zacks.com
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseTG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 month ago · zacks.com
TGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TGTX